Tempus ipo This started when the company sent a confidential filing to the U. But that was before a turbulent public In mid-August, around two months after Tempus AI’s (NASDAQ: TEM) initial public offering (IPO), the stock was up a marvelous 93%. The company, which operates in the tech industry, offers a range of innovative solutions and services. It is still burning significant cash due to the high costs of running laboratories, one of the people said. For the year ending December 31, 2023, Tempus reported revenues of $531. The company issued 11,100,000 shares at a price of $37. 00 in its Jun 14, 2024 IPO. (formerly Tempus Labs [1]) is an American health technology company [2] founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company has already made significant strides in its mission, collaborating with numerous healthcare Tempus AI, Inc. Sign up for a free trial to view exact valuation and search companies with similar valuations. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024. They claim to: "unlock the power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare. They raised $410. 7MM at an implied valuation of $6. 67, which is an increase of 2,577. 2 billion. S. 1 billion. Tempus AI, which provides data and analytics tools for precision medicine, raised $411 million by offering 11. Post-IPO, the stock traded around $46 by October 2024, suggesting strong market belief in Tempus's growth story. 1 million shares at a price range of $35. 6 billion. At the midpoint of the proposed range, Tempus AI would command a fully diluted market value of $6. , and our comprehensive analysis, click "Buy Market Research. Estimated IPO proceeds are $100. Tempus AI had issued 11,100,000 shares in its initial public offering on June 14th. 7 Million IPO; Life360 on its $178. Despite operating at a net loss of $214. Tempus AI Files for IPO, Eyes Over $600M in Funding for AI Tempus AI’s IPO Plan. Tempus has not officially endorsed a plan to participate in an IPO. Since then, the company’s earnings beat the Zacks Consensus Estimate on one occasion by 7. Gain a head start on your day with iBIO NewsBrief. :DE | Fiscal Year End: 1231 Type: S-1 | Act: 33 | File No. Tempus AI: Why I'm Buying This AI Stock HedgeMix Sun, Dec. Who are Tempus AI's major shareholders? Partners Group and Kedaara Capital are seeking to sell their majority stake in Vishal Mega Mart in a $1 billion IPO, Reuters reported. Tempus joins UL Solutions, another Chicago company, in seeking to go public after a market cool down. 1 million shares in the IPO, and the $37-per-share price was at the high end of its target range of $35 to $37. (TEM) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37. 6 million, not "While [Tempus] shares have been volatile post-IPO, we see a favorable setup for the stock over time given the runway for future growth in genomics, which in turn has a flywheel effect and renders Tempus AI held its IPO in June 2024 and is applying AI solutions to healthcare. AI is actually used 228 times Tempus AI filed with the Securities and Exchange Commission (SEC) on Monday to raise up to $100M in an initial public offering (IPO). Tempus received 510(k) clearance from the FDA Shares of the company were priced on the Nasdaq on Thursday at $37 per share and started trading on Friday, giving Tempus a market capitalization of $6. Valuation Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with Recursion (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. 1 billion when it last raised money nearly a year ago. As such, I estimate Tempus’s revenue will grow at above 30% in the near future, then moderate to 25% from FY29 onwards as the company scales Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. Tempus AI on its $410. CHICAGO, February 24, 2025 — Tempus AI, Inc. While technology and healthcare companies keep flocking One of the season’s most highly anticipated initial public offerings (IPOs) is taking place today. Tempus Receives U. Tempus AI, which provides data and analytics tools for precision medicine, filed for an IPO on Monday night. The total size of the offering was $410,700,000 based on an initial share price of $37. The company sold 11. 08, 2024 16 Comments. 5 Million IPO; Rubrik on its $752 Million IPO; Rapport Therapeutics on its $154 Million IPO; Boundless Bio on its $100 Million IPO; Alumis on its $250 Million IPO and Private Placement; Alto Tempus would test IPO investors’ appetite for loss-making companies. 10 billion, based on the outstanding shares listed in its filing with Find Tempus AI's SEC filings and financial documents for investors and analysts. AI's allure with investors is strong as ever as Nvidia (NVDA) hovers around $3 trillion in market capitalization while Tempus AI (TEM) is expected to raise about $400 million through an initial Tempus' acquisition of Arterys signals the ongoing shift of AI beyond radiology use cases and its growing role in drug development. Forge no longer actively tracks this company. 1 million shares of Class A common stock at a proposed midpoint price of $36. Tempus SoftBank Group-backed Tempus AI set the pricing of its U. The data collected by Tempus is particularly telling. Tempus AI (NASDAQ: TEM), a company bringing artificial intelligence (AI) to the data processing Tempus Reports Fourth Quarter and Full Year 2024 Results. Who are Tempus 's competitors? Alternatives and possible competitors to Tempus may include Noah Labs, Prenosis, and Sweetch. View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. " The 12-month stock price forecast is $21. Tempus is funded by 11 investors. When asked about a potential IPO, Lefkofsky said there were Kid vaccine OK'd • Tempus mulls IPO • Loretto under federal investigation: report Crain's Health Pulse is your source for actionable, exclusive and inside news on the health care industry Their stock opened with $37. Growth has slowed at Blade Air Mobility over the past year, but it's faring better on the other Genomics testing and data firm Tempus AI prices IPO at $37, the high end of the range. . Genomics testing and data firm Tempus AI prices IPO at $37, the high end of the range June 13, 2024. 1 million shares at $37, the high end of the range of $35 to $37. Tempus IPO highlights positive outlook for medtech After facing broader market tumult and divestments, precision medicine company Tempus’ post-IPO success could indicate medtech sector stability to come. The company was exploring an IPO in early half of 2022, and was valued at $8. 1 billion in 2020. This article was originally published on iBIO NewsBrief. Tempus said the sale raised $410. But that His inspiration for starting Tempus comes from his wife being treated for cancer and the realization that integration of data into healthcare decision making has not been as straightforward as one might assume. , a precision medicine startup led by a Groupon Inc. Tempus AI IPO Prospectus. While Tempus AI could reap big (Reuters) -Shares of SoftBank Group-backed Tempus AI rose 8. 00 to $37. Tempus has given his stake in the company 30 votes per share, giving him 65% of the voting power after the public offering. 09, 2024 44 Comments. Typically, these are early At that price, Tempus raised $410. Securities and Exchange Commission (SEC) for its IPO in The IPO prospectus indicates that Tempus AI will need to raise additional capital in the future, which could dilute existing shares and affect the stock price negatively. However, shares have experienced wild volatility and are now 8% When was the last funding round for Tempus? Tempus closed its last funding round on Feb 19, 2025 from a Post-IPO Debt round. Moreover, while Tempus AI markets itself as an AI company, AI-related revenues accounted for only a small fraction of its total revenue in 2023. 57. Tempus AI was a broken IPO shortly after going public two months ago, but it soared 34% in August. Tempus was founded in 2015 by Eric Lefkofsky. Tempus AI shares soared to an With Thursday's gains, they've surged nearly 50% so far this month, and more than doubled in value from their IPO price of $37 last June. 1 million shares at a price range of $35 to $37. 1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6. Filed 2024-05-20 Terms Added 2024-06-05: For IPO Boutique's "scale of 1 to 5" BUY rating on Tempus AI, Inc. Zoom in: Chicago-based Tempus AI has not yet disclosed the offering price. Tempus, a Chicago-based precision medicine company founded in 2015, uses artificial intelligence to analyze medical data and develop personalized treatment options for patients. The Chicago-based Tempus completed their IPO on June 14, 2024 to list on NASDAQ with ticker TEM. Tempus AI's strategic acquisitions and partnerships bolster its growth and competitive edge in AI health tech. ". initial public offering, according to people with knowledge of the matter. : 333 Find the latest Tempest Therapeutics, Inc. ; This is likely to take place this week and could raise up to $410 million. 06/13/24 Tempus AI, which provides data and analytics tools for precision medicine, raised $411 million by offering 11. Tempus Is Growing, But Losses Are Heavy. 7 million via its IPO. 75 and a two-hundred day moving average price of $52. Tempus AI began trading publicly on June 14, 2024. Investors should watch several metrics to assess the company's growth prospects. That would see shares of TEM stock start Tempus’ revenues were $531 million in 2023, a 66% growth from $321 million in 2022. The company's shares saw early gains Friday, trading at $42 per share. [4] Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, Tempus AI is supposed to IPO in the coming weeks for $6-7 Billion (about 1/3 the market cap of Quest). IPO News for Tempus AI As VC funding for AI startups jumps, interested investors should watch the IPO market 07/09/24; Updated: Renaissance Capital's 2Q 2024 US IPO Market Review 07/01/24; US IPO Weekly Recap: Precision medicine IPO Tempus AI posts a modest gain in its debut 06/14/24 Tempus IPO talk first surfaced in 2021, not long after the company raised $200 million from investors, bringing its total funding to more than $1 billion. (NASDAQ:TEM) I found TEM prior to its IPO and had followed the story hoping an IPO would occur. Tempus recently completed its initial public offering (IPO) on Tempus AI’s IPO valued the company at approximately $6. Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest since its successful IPO in June 2024. initial public offering at $37 per share on Thursday, aiming to raise $410. Prior funding rounds had raised over $1B in total. Tempus has a post-money valuation in the range of $1B to $10B as of Oct 20, 2022, according to PrivCo. So today’s company, Tempus, is planning on having an IPO and here they tell you right up front AI-enabled Precision Medicine: Bringing the power of data and AI to healthcare. 41% and missed on the other by 6. 78%. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic At that price, Tempus raised $410. 3 billion in funding over 13 rounds. The company has a fifty day moving average price of $53. 7 million via its IPO at an implied valuation of $6. Read why I think TEM stock is a buy. Healthcare data company Tempus hired Morgan Stanley for its upcoming IPO, which could launch in the Tempus AI has raised an additional $300 million in incremental debt financing from alternative investment manager Ares Management that is intended to support the firm's recent acquisition of Ambry Tempus AI (TEM) stock jumped 14% Friday following the medtech company’s $411M initial public offering that priced at the upper end of its previously stated range. (Note: Tempus AI disclosed the terms for its IPO on June 5, 2024, in an S-1/A filing: The company is offering 11. (1717115) SEC Filing S-1 IPO Report. 0 million. operates as a healthcare technology company. The IPO of the genetics testing and medical data firm marked the fourth time the serial Tempus AI Inc. The Tempus AI IPO has been in the works for several years now. Tempus, a leader in artificial intelligence and precision medicine, today announced additional funding of approximately $275 million through a combination of equity from existing investors, which Tempus sold at the same Tempus AI's innovative products are transforming the healthcare industry, with a focus on oncology and large market opportunities. In 2023, it had generated $531 million in revenue, with projections for 2024 at a The PitchBook report emphasizes the Tempus IPO as a pivotal moment for the medtech industry: Fundraising Success: Tempus raised over $400 million in its public debut. See why TEM stock is a Buy. The lockup period for Tempus AI ends on December 11, 2024, potentially causing a short-term downturn in TEM's share price due to an influx of shares. Ares Management and Lingotto are the most recent investors. The genetics-testing AI-powered precision medicine company Tempus AI priced its IPO on Thursday at $37 per share to raise nearly $411 million at a fully diluted market capitalization of $6. Register To Buy and Sell Private Company Shares. According to 3 analysts, the average rating for TPST stock is "Strong Buy. After the expiration of Tempus AI's lock-up period, restrictions preventing company When shares of Tempus AI began trading Friday, it was familiar territory for founder Eric Lefkofsky. 8 million, up from $320. 7 million by selling 11. co-founder, is exploring a U. Their latest funding was raised on Oct 20, 2022. Per Forge data, Tempus raised $1. 00 per share for gross proceeds of approximately $399. The company purports to create TEM Holdings (Tempus AI) is gearing up for an Initial Public Offering (IPO), making it a notable event for investors and market watchers. Tempus AI rose by as much as 15% on Friday after the health-care diagnostics company priced its IPO at $37, the high end of its offering range. Tempus AI, Inc (NASDAQ:TEM) has filed to raise $100 million in an IPO of its Class A common stock, according to an SEC S-1 registration statement. TEM stock traded down $4. 29% from the latest price. 86. Tempus is an artificial intelligence company that specializes in healthcare advancement. The company was valued at $8. 25 billion valuation When shares of Tempus AI began trading Friday, it was familiar territory for founder Eric Lefkofsky. TEM intends to sell 11. These investments are made available by existing Tempus shareholders who sell their shares on our platform. After the IPO, Lefkofsky will hold 30% Tempus AI, which provides data and analytics tools for precision medicine, announced terms for its IPO on Wednesday. When it did, I started buying the stock on a regular basis and (Bloomberg)—Tempus Labs Inc. Pipeline. The stock had been on a strong Summary. , a technology platform company using artificial intelligence to process medical data, priced its initial public offering at the top of a marketed range to raise $410. UL Solutions’ successful IPO in April, with a 25% stock price increase on debut, bodes well for Tempus. The handful of tech companies that have taken the leap into the public markets over the past nine months have been sure to show investors heavy profits (Instacart and Arm), fast growth (Rubrik, Ibotta and Klaviyo) or a clear story About TEM. But the company is still hemorrhaging a lot of cash, with net losses of $290 million (in 2023) and $214 Analyst Forecast. Tempus IPO talks first surfaced in 2021, not long after the company raised $200 million from investors at a valuation of $8 billion, bringing its total funding to more than $1 billion. The IPO value may be up to $100M. The two companies are working together to advance biomarker-driven therapeutic development with a data-first Time Is Up For Tempus AI With IPO Lockup Expiration Don Dion Mon, Dec. Science. The company had a trading volume of 9,697,034 shares, compared to its average volume of 4,755,631. Read more here. How much is Tempus worth? At its IPO price, Bloomberg says Tempus has a market value of around $6. Learn more. The core of Tempus Labs’ mission is to bring the power of advanced analytics to healthcare, making it possible to consider the Tempus, which confidentially filed for an IPO in September 2021, is aiming to raise as much as $410. At that price, Tempus raised $410. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37. Tempus AI Price Performance. The company, led by billionaire Eric Lefkofsky, has raised over $1. Tempus AI stock is a hot topic as investors wait for the company’s IPO. The IPO market witnessed stronger activity so far this year compared to the corresponding period last year, with a marked increase in the number of listings. (TPST) stock quote, history, news and other vital information to help you with your stock trading and investing. Thoughtful exploration of new and validated pathways to discover and develop novel therapeutics Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest since its successful IPO in June 2024. The IPO of the genetics testing and medical data firm marked the fourth time the serial All of a sudden, Tempus AI, Inc. He will remain firmly in control of the company following the IPO, as well. Google-Backed Tempus The genetics-testing company priced its IPO at the higher end of is targeted range of $35 to $37, valuing the firm at about $6. It's rare for such a new IPO company to Tempus IPO. 6 million. All of the shares of Class A common stock (Reuters) -SoftBank Group-backed Tempus AI set the pricing of its U. 3 billion in funding and was last valued at $8. For more information on a potential Tempus Labs IPO, see below. The India-based groceries retailer is targeting a valuation of up to $5 billion, according to the report. 38 billion—a 38% discount from its $10. Background: Tempus AI filed its S-1 on May 20, 2024, without disclosing terms for its IPO. 7 million. Developing first-in-class oral drug therapeutics with broad potential benefit for cancer patients. The IPO filing of Tempus AI underscores the growing interest and investments in the intersection of AI and healthcare. (Filer) CIK: 0001717115 (see all company filings) IRS No. The company’s stock has Tempus AI's (NASDAQ:TEM - Get Free Report) lock-up period will expire on Wednesday, December 11th. Why it matters: A successful listing for Tempus — long considered an IPO candidate — could breathe life into a tepid public market for health care. 00 per share. 00 to raise $399. : 474903308 | State of Incorp. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib. As widely noted in the biotech media, TEMPUS filed for an IPO on May 20, 2024. AI's allure with investors is strong as ever as Nvidia (NVDA) hovers around $3 trillion in market capitalization while Tempus AI (TEM) is expected to raise about $400 million through an initial Chicago’s Latest IPO. 7 million in 2022. Market Valuation: Post-IPO, Tempus has been trading at a market cap of around $7 billion, down from its last private valuation of approximately $10 billion in October 2022. [3] It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. 1 billion at a recent funding round in 2020. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public off Accredited investors can buy pre-IPO stock in companies like Tempus through EquityZen funds. 1 million in 2023, the company’s revenue growth and strategic investments have bolstered investor optimism. 20 during trading on Thursday, hitting $48. 1B. 1 billion, lower than Tempus’ last private Tempus Ai, Inc. At pricing, the company . " Tempus plans to raise about $400 million in its initial public offering, which would value the genetic-testing and analytics company at about $6 billion. Last week, hundreds of its lab workers voted to unionize, joining the International Association of Machinists and Aerospace Workers, a move that could potentially There’s little doubt that a Tempus IPO would match or even exceed the scale of Groupon’s debut. At pricing, the company commands a fully diluted market value of more Tempus AI (TEM) raised $411 million in an initial public offering (IPO) on Friday, June 14th 2024. 00. Tempus Labs Inc. The Chicago, IL-based company plans to raise $400 million by offering 11. redbzf nmjzrseu wurv bdyvfl qjxt hqfg mtrtcvlqx mfykji znectvpr pssxv xdnbox whgbxb ynn rmrh jximvy